

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED**

**通用環球醫療集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 2666)**

### **(1) RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER; AND (2) APPOINTMENT OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER**

The Board announces that with effect from 25 March 2026:

- (1) Mr. Wang Wenbing resigned as an executive Director, the chief executive officer and a member of the Risk Control Committee, due to his other work arrangements; and
- (2) Mr. Xia Qi was appointed as an executive Director, the chief executive officer and a member of the Risk Control Committee.

### **RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Genertec Universal Medical Group Company Limited (the “**Company**”) announces that Mr. Wang Wenbing (“**Mr. Wang**”) resigned as an executive Director, the chief executive officer and a member of the risk control committee of the Board (the “**Risk Control Committee**”) due to his other work arrangements, with effect from 25 March 2026.

Mr. Wang has confirmed that he has no disagreement with the Board and he is not aware of other matters in connection with his resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. Wang for his valuable contribution to the Company’s development during his tenure.

### **APPOINTMENT OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER**

The Board is pleased to announce that with effect from 25 March 2026, Mr. Xia Qi (“**Mr. Xia**”) was appointed as an executive Director, the chief executive officer and a member of the Risk Control Committee.

**Mr. Xia Qi**, aged 50. Mr. Xia began his career in July 1998, serving successively as a cadre, deputy director of a division, director of a division, and deputy director of the Research Office of the United

Front Work Department of the Central Committee of the Communist Party of China. In September 2018, he was transferred to the General Office of the State Council, where he worked on matters related to education and healthcare. In June 2024, he joined China General Technology (Group) Holding Co., Ltd., where he serves as the director of the General Office (the Party Committee Office and the General Manager's Office).

Mr. Xia graduated from the Department of Information Management at Shandong University majoring in Information Science in July 1998, and obtained a Master's degree of Public Administration from Central University of Finance and Economics in May 2013.

Mr. Xia and the Company entered into a service contract on 25 March 2026, pursuant to which, Mr. Xia was appointed since 25 March 2026, and such appointment could be terminated by either Mr. Xia or the Company by giving not less than three months' notice in writing. Mr. Xia will hold office until completion of the next annual general meeting of the Company following his appointment, and will then be eligible for re-election at that general meeting. Pursuant to the service contract, the remuneration of Mr. Xia as an executive Director and the chief executive officer will be considered by the remuneration committee of the Board and subsequently determined and approved by the Board with reference to his duties and responsibilities in the Company.

As at the date of this announcement, save as disclosed above, Mr. Xia did not (i) have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company; (ii) have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) hold any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iv) hold other positions with other members of the Group.

Save as disclosed above, to the best of the knowledge, information and belief of the Directors after having made all reasonable enquiries, there is no information in relation to the appointment of Mr. Xia that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

The Board would like to extend its warm welcome to Mr. Xia's role as executive Director.

By order of the Board  
**Genertec Universal Medical Group Company Limited**  
通用環球醫療集團有限公司  
**Chen Shisu**  
*Chairman of the Board*

Beijing, PRC, 25 March 2026

*As at the date of this announcement, the executive directors of the Company are Mr. Chen Shisu (Chairman), Mr. Xia Qi and Ms. Wang Lin; the non-executive directors of the Company are Mr. Tong Chaoyin, Mr. Lin Chunhai, Mr. Huang Youjie and Mr. Ma Wanming; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.*